Home/Pipeline/Xtandi

Xtandi

Prostate Cancer

MarketedActive

Key Facts

Indication

Prostate Cancer

Phase

Marketed

Status

Active

Company

Royalty Pharma

About Royalty Pharma

Royalty Pharma is a pioneer and dominant leader in the biopharmaceutical royalty financing sector, having deployed over $25 billion in capital since its 1996 founding. Its mission is to fund the next wave of biopharma innovation by providing non-dilutive capital to partners in exchange for a share of future royalty streams. The company's strategy centers on building a diversified portfolio of royalties across therapeutic areas and development stages, leveraging deep scientific and financial expertise to structure bespoke deals that fuel R&D while generating predictable, long-duration cash flows for investors.

View full company profile

Therapeutic Areas

Oncology Cystic Fibrosis HIV Cardiovascular Autoimmune Diseases Neurology

Other Prostate Cancer Drugs

Drug	Company	Phase	Status
APVO442	Aptevo Therapeutics	Preclinical	Active
APVO452	Aptevo Therapeutics	Discovery	Active
BIO 300	Humanetics Corp.	Not Specified	Active
Opaganib	RedHill Biopharma	Phase 2	Active
Small-Molecule Therapeutic	AIkido Labs	Pre-clinical	Active
Leronlimab	CytoDyn	Preclinical	Phase in progress
ENV105	Kairos Pharma	Phase 2	Active
AI for Prostate Cancer	Invenio Imaging	Research	Active
Mitomic™ Test for Prostate Cancer	MDNA Life Sciences	Development/Validation	Active
Immunomodulator Platform	OmniCyte	Research	Active
Prostate cancer 'super test'	EDX Medical	Development	Active
PSMA-Dex	DexTech Medical	Pre-clinical	Active